Angiotensins TRIZ Cases

Mas receptor activation by Ang-(1-7) derivatives targets cancer-induced bone pain while reducing reliance on opioids and their harmful effects.

Angiotensin II receptor agonists modulate sympathetic responses to prevent skeletal muscle cramps without causing fluid retention or elevated blood pressure.

Detect anti-AT1-receptor antibodies in patient blood samples using luciferase or ELISA immunoassays to identify disease markers.

Single-step enzymatic hydrolysis replaces unreliable bacterial fermentation to produce stable, bland-tasting ACE inhibiting peptides with consistent purity.

Thioether bridge links angiotensin residues to form stable cyclic peptides, resolving rapid degradation of linear analogs.

AT2R selective peptide agonists reverse collagen deposition and inflammation, surpassing the limited 7% mortality reduction of conventional ACE inhibitors.

A polyamide resin composition incorporating citric acid and EDTA to form a dense oxide film on the polymer surface.

Retro-inverse angiotensin-(1-9) peptides use D-amino acid inversion to resist enzymatic degradation and extend plasma half-life.

Urinary to plasma C-type natriuretic peptide ratio identifies renal fibrosis early, enabling timely intervention before chronic kidney disease progression.

Proline-3-amino-2-methoxy benzoic acid scaffolds stabilize reverse turns in angiotensin II analogs, resolving cytotoxicity and stability issues.

Stable cyclic angiotensin analogs extend half-life to reduce tumor size while resisting rapid enzymatic degradation.

Peptidic angiotensin receptor antagonists reduce blood pressure while preventing fetal complications associated with sartan class drugs.

Modified peptidic sequences eliminate partial agonist activity and fetal exposure while controlling blood pressure in pregnancy.

ACE2 polypeptides convert angiotensin II to angiotensin 1-7, reducing inflammation and neovascularization without severe side-effects.